Timing the SARS-CoV-2 index case in Hubei province.

Permalink
https://escholarship.org/uc/item/699344hs

Journal
Science (New York, N.Y.), 372(6540)

ISSN
0036-8075

Authors
Pekar, Jonathan
Worobey, Michael
Moshiri, Niema
et al.

Publication Date
2021-04-01

DOI
10.1126/science.abf8003

Peer reviewed
CORONAVIRUS
Timing the SARS-CoV-2 index case in Hubei province

Jonathan Pekar1,2, Michael Worobey3,4, Niema Moshiri5, Konrad Scheffer3, Joel O. Wertheim6*

Understanding when severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged is critical to evaluating our current approach to monitoring novel zoonotic pathogens and understanding the failure of early containment and mitigation efforts for COVID-19. We used a coalescent framework to combine retrospective molecular clock inference with forward epidemiological simulations to determine how long SARS-CoV-2 could have circulated before the time of the most recent common ancestor of all sequenced SARS-CoV-2 genomes. Our results define the period between mid-October and mid-November 2019 as the plausible interval when the first case of SARS-CoV-2 emerged in Hubei province, China. By characterizing the likely dynamics of the virus before it was discovered, we show that more than two-thirds of SARS-CoV-2-like zoonotic events would be self-limited, dying out without igniting a pandemic. Our findings highlight the shortcomings of zoonosis surveillance approaches for detecting highly contagious pathogens with moderate mortality rates.

In late December of 2019, the first cases of COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were described in the city of Wuhan in Hubei province, China (1, 2). The virus quickly spread within China (3). The cordon sanitaire that was put in place in Wuhan on 23 January 2020 and mitigation efforts across China eventually brought about an end to sustained local transmission. In March and April 2020, restrictions across China were relaxed (4). By then, however, COVID-19 was a pandemic (5).

A concerted effort has been made to retrospectively diagnose the earliest cases of COVID-19 and thus determine when the virus first began transmitting among humans. Both epidemiological and phylogenetic approaches suggest an emergence of the pandemic in Hubei province at some point in late 2019 (2, 6, 7). The first described cluster of COVID-19 was associated with the Huanan Seafood Wholesale Market in late December 2019, and the earliest sequenced SARS-CoV-2 genomes came from this cluster (8, 9). However, this market cluster is unlikely to have denoted the beginning of the pandemic, as COVID-19 cases from early December lacked connections to the market (7). The earliest such case in the scientific literature is from an individual retrospectively diagnosed on 1 December 2019 (6). Notably, however, newspaper reports document retrospective COVID-19 diagnoses recorded by the Chinese government going back to 17 November 2019 in Hubei province (10).

These reports detail daily retrospective COVID-19 diagnoses through the end of November, suggesting that SARS-CoV-2 was actively circulating for at least a month before it was discovered. Molecular clock phylogenetic analyses have inferred the time of the most recent common ancestor (tMRCA) of all sequenced SARS-CoV-2 genomes to be in late November or early December 2019, with uncertainty estimates typically dating to October 2019 (7, 11, 12). Crucially, though, this tMRCA is not necessarily equivalent to the date of zoonosis or index case infection (13, 14) because coalescent processes can prune basal viral lineages before they have the opportunity to be sampled, potentially pushing SARS-CoV-2 tMRCA estimates forward in time from the index case by days, weeks, or months. For a point of comparison, consider the zoonotic origins of the HIV-1 pandemic, whose tMRCA in the early 20th century coincided with the urbanization of Kinshasa, in what is now the Democratic Republic of the Congo (15, 16), but whose cross-species transmission from a chimpanzee reservoir occurred in southeast Cameroon, likely predating the tMRCA of sampled HIV-1 genomes by many years (17). Despite this important distinction, the tMRCA has been frequently conflated with the date of the index case infection in the SARS-CoV-2 literature (7, 18, 19).

Here, we combine retrospective molecular clock analysis in a coalescent framework with a forward compartmental epidemiological model to estimate the timing of the SARS-CoV-2 index case in Hubei province. The inferred dynamics during these unobserved early days of SARS-CoV-2 highlight challenges in detecting and preventing nascent pandemics.

We first explored the evolutionary dynamics of the first wave of SARS-CoV-2 infections in China. We used Bayesian phylodynamics (20) to reconstruct the underlying coalescent processes using a Bayesian Skyline approach for 583 SARS-CoV-2 complete genomes, sampled in China between when the virus was first discovered at the end of December 2019 and the last of the non-reintroduced circulating virus in April 2020. Applying a strict molecular clock, we inferred an evolutionary rate of $7.90 \times 10^{-3}$ substitutions per site per year [95% highest posterior density (HPD): $6.64 \times 10^{-4}$ to $9.27 \times 10^{-3}$]. The tMRCA of these circulating strains was inferred to fall within a 34-day window with a mean of 9 December 2019 (95% HPD: 17 November to 20 December) (Fig. 1). This estimate accounts for the many disparate inferred rooting orientations [see supplementary text and (21)]. Notably, 78.7% of the posterior density postdates the earliest published case on 1 December, and 95.1% postdates the earliest reported case on 17 November. Relaxing the molecular clock provides a similar tMRCA estimate, as does applying a Skygrid coalescent approach (fig. S1). The recency of this tMRCA estimate in relation to the earliest documented COVID-19 cases obliges us to consider the possibility that this tMRCA does not capture the index case and that SARS-CoV-2 was circulating in Hubei province before the inferred tMRCA.

If the tMRCA postdates the earliest documented cases, then the earliest diverged SARS-CoV-2 lineages must have gone extinct (Fig. 2). As these early basal lineages disappeared, the tMRCA of the remaining lineages would move forward in time (fig. S2). Thus, we interrogated the posterior trees sampled from the phylodynamic analysis to determine whether this time of coalescence had stabilized before the sequencing of the first SARS-CoV-2 genomes on 24 December 2019 or whether this process of basal lineage loss was ongoing in late December and/or early January. Notably, these basal lineages need not be associated with specific mutations, as the phylodynamic inference reconstructs the coalescent history, not the mutational history (20).

We find only weak evidence for basal lineage loss between 24 December 2019 and 13 January 2020 (fig. S3A). The root tMRCA is within 1 day of the tMRCA of virus sampled on or after 1 January 2020 in 78.5% of posterior samples (fig. S3B). The tMRCA of genomes sampled on or after 1 January 2020 is 3 days later than the tMRCA of all sampled genomes. By contrast, the mean tMRCA does not change when considering genomes sampled on or after 1 January 2020 versus on or after 13 January 2020. This consistency indicates a stabilization of coalescent processes at the start of 2020, when an estimated total of 1000 people had been infected with SARS-CoV-2 in Wuhan (22). Nonetheless, to account for the weak signal of a delay in reaching a stable coalescence (i.e., the point in time at which basal lineages cease to be lost), we identified the tMRCA for all viruses sampled on or after 17 November 2019 in Hubei province (10).
Phylogenetic analysis alone cannot tell us how long SARS-CoV-2 could have circulated in Hubei province before the tMRCA. To answer this question, we performed forward epidemic simulations (23). These simulations were initiated by a single index case using a compartmental epidemiological model across scale-free contact networks (mean number of contacts: 16). This compartmental model was previously developed to describe SARS-CoV-2 transmission dynamics in Wuhan (22). This model, termed SAPHIRE, includes compartments for susceptible (S), exposed (E), pre-symptomatic (P), unascertained (A), ascertained (I), hospitalized (H), and removed (R) individuals. Our simulations used parameters from the time period before COVID-19 mitigation efforts, from 1 January through 22 January 2020 (table S1), based on the work of Hao et al. (22).

We analyzed 1000 epidemic simulations that resulted in ≥1000 total infected people. These simulated epidemics had a median doubling time of 4.1 days (95% range across simulations: 2.7 to 6.7), matching premitigation incidence trends in Wuhan (table S2).

We simulated coalescent processes across the transmission network to determine the tMRCA of the virus at the end of the simulation. This approach allowed us to determine the distribution of the expected number of days between index case infection and the stable coalescence (i.e., tMRCA) (Fig. 2). The median number of days between index case infection and this tMRCA was 8.0 days (95% range: 0.0 to 41.5 days) (Fig. 3A). The median time between index case infection and the first person exiting the presymptomatic phase (i.e., ascertained or unascertained infection) was 5.7 days (95% range: 0.9 to 15.7 days).

As a robustness check, we also simulated epidemics with more densely and more sparsely connected contact networks (mean: 26 and 10 contacts, respectively), rescaling the per-contact transmission rate to maintain empirical epidemic growth dynamics. We also explored the effects of faster (mean: 3.1 days; 95% range: 2.0 to 5.1 days) and slower (mean: 5.3 days; 95% range: 3.6 to 7.5 days) epidemic doubling times (table S2). Slower transmission rates led to more days between the index case and the stable coalescence, but modifying the density of the contact network had minimal effect on this time interval (fig. S4).

To estimate the date of infection for the index case in Hubei province, we combined the retrospective molecular clock analysis with the forward epidemic simulations (fig. S5). We identified the stable tMRCA in the posterior trees as an anchor to the real-world calendar dates and then extended this date back in time according to the number of days between the index case infection and the time of stable coalescence from the compartmental epidemic simulations. However, a random sample of tMRCA's and days from index case infection to coalescence will not produce epidemiologically meaningful results because many of these combinations do not precede the earliest dates of reported COVID-19 cases. Therefore, we implemented a rejection sampling-based approach to generate a posterior distribution of dates of infection for the Hubei index case, conditioning on at least one individual who had progressed past the presymptomatic stage in the simulated epidemic before the date of the first reported COVID-19 case (see materials and methods and fig. S6).

In our primary analysis, we assume that 17 November represents the first documented case of COVID-19 (ascertained or unascertained in the SAPHIRE model). Under this assumption, the median number of days between index case infection and stable coalescence after rejection sampling is 37 days (95% HPD: 12 to 55 days) (Fig. 3B). Consequently, the index case in Hubei likely contracted SARS-CoV-2 on or around 4 November 2019 (95% upper HPD: 15 October; 99% upper HPD: 7 October) (Fig. 3C).

This time frame for the Hubei index case is robust (fig. S7). Epidemic simulations with faster or slower transmission rates and more or less densely connected contact networks produce similar date estimates. Furthermore, using the root tMRCA from the sampled posterior trees, rather than adjusting for the shifting coalescence between 24 December 2019 and 1 January 2020, produces a median date of 3 November (95% upper HPD: 14 October; 99% upper HPD: 4 October). Incorporating a relaxed molecular clock or adjusting the coalescent prior assumption (Skyline versus Skygrid) also had minimal effect.

If we enforce that there must be at least one ascertained case in our simulations before 1 January 2020 (i.e., at the time of stable coalescence) for each tree in the posterior sample.
Pekar et al., Science 372, 412–417 (2021) 23 April 2021

Fig. 2. Hypothetical coalescent scenarios depicting how the time between index case infection and time of stable coalescence can vary on the basis of stochastic extinction events of basal viral lineages.

Coalescence can occur within or contemporaneously with the index case (upper left) or, in cases infected later in the course of the epidemic, with one (upper right) or more (lower left) basal lineages going extinct. In extreme cases, the epidemic can persist at low levels for a long time before stable coalescence (lower right).
prevalence of this virus was too low to permit its discovery and characterization for weeks or months. By the time that COVID-19 was first identified, the virus had firmly established itself in Wuhan. This delay highlights the difficulty in surveillance for novel zoonotic pathogens with high transmissibility and moderate mortality rates.

The high extinction rates we inferred suggest that spillover of SARS-CoV-2–like viruses may be frequent, even if pandemics are rare (28). Furthermore, the same dynamics that characterized the establishment of SARS-CoV-2 in Hubei province may have played out all over the world, as the virus was repeatedly...
introduced but only occasionally took hold (29, 30). The reports of cases in December 2019 and January 2020 in France and California that did not establish sustained transmission fit this pattern (31–33). However, our results suggest that polymerase chain reaction evidence of SARS-CoV-2 in wastewater outside of China before November 2019 is unlikely to be valid (34), and the suggestion of international spread in mid-November or early December 2019 should be viewed with skepticism (35–37), given that our results suggest that fewer than 20 people were infected with SARS-CoV-2 at this time (table S4 and fig. S11). Our results also refute claims (38) of large numbers of patients requiring hospitalization because of COVID-19 in Hubei province before December 2019 (figs. S13 and S14). Nevertheless, SARS-CoV-2 may be detectable in archived wastewater samples or other biomaterials from Hubei province from early to mid-November 2019, should they exist, and incorporating these types of data in our model could further refine our timing estimates. Moreover, wastewater detection may present the best chance of early detection of future pandemics during the early phase of spread for which we estimate very low numbers of infections (39).

Even though all of the earliest documented cases of COVID-19 were found in Hubei province, we cannot discount the possibility that the index case initially acquired the virus elsewhere. Nonetheless, our dating inference is insensitive to geography. Furthermore, our results suggest that if the virus first emerged in a rural community, it would have needed to migrate to an urban setting to avoid extinction. The lack of reports of COVID-19 elsewhere in China in November and early December suggests that Hubei province is the location where human-to-human transmission chains were first established.

The circumstances surrounding the emergence of SARS-CoV-2 in Hubei province remain shrouded. Although SARS-CoV-2 is repeatedly adapting to spread among humans (40, 41), our findings do not reveal whether the virus that first emerged was less fit than the virus that spread throughout China. Nevertheless, the inferred timing of the index case is generally similar in both of these scenarios because less-fit viruses in our simulations that went extinct tended to do so very quickly. It is yet unknown whether the virus emerged directly from its animal reservoir [presumably horseshoe bats (42, 43)] or first circulated in and possibly adapted to an intermediate host. Our estimates for the timing of the Hubei index case further distance this individual from the outbreak at the Huanan Seafood Wholesale Market. Finding the animal reservoir or hypothetical intermediate host will help to further narrow down the date, location, and

---

**Fig. 4. Epidemic growth in compartmental simulations.** (A) Estimated total number of people infected in late 2019. Dark purple shading represents central 50% HPD, intermediate purple shading represents central 95% HPD, and light purple represents central 99% HPD. (B) Estimated total number of people infected in late 2019 for a two-phase epidemic. (C) Number of people infected over time in a sample of epidemic simulations that established (purple; n = 30) and went extinct (gray; n = 70). The y axis transitions to log scale once ≥10 people are infected at any given time. The lower panel shows the proportion of simulations that still have at least 1 infected individual over time (persisting epidemics in purple; extinct epidemics in gray). (D) Sample (n = 10) of two-phase epidemic simulations transitioning from less-fit phase 1 (blue) to more-fit phase 2 (purple). Each line represents a single simulation and its transition over time. The lower panel shows the average proportion of phase 1– to phase 2–infected individuals over time.
circumstances of the original SARS-CoV-2 infection in humans. However, even in the absence of that information, coalescent-based approaches permit us to look back beyond the tMRCA and toward the earliest days of the COVID-19 pandemic. Although there was a pre-tMRCA fuse to the COVID-19 pandemic, it was almost certainly very short. This brief period of time suggests that future pandemics with similar characteristics to those of the COVID-19 pandemic permit us to look back beyond the tMRCA and to the Fall of 2019 data in Wuhan China indicates early disease activity in the fall of 2019” (Harvard Library Office for Scholarly Communication, 2020; https://dash.harvard.edu/handle/1/42659767).

REFERENCES AND NOTES
1. N. Zhu et al., N. Engl. J. Med. 382, 727–733 (2020).
2. Q. Li et al., N. Engl. J. Med. 382, 1199–1207 (2020).
3. World Health Organization, “Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)” (World Health Organization, 2020; www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19).
4. H. Fei et al., Lancet Reg. Health West Pac. 3, 100032 (2020).
5. World Health Organization, “WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020” (World Health Organization, 2020; www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020).
6. C. Huang et al., Lancet 395, 497–506 (2020).
7. X. Zhang et al., Nature 583, 437–440 (2020).
8. F. Wu et al., Nature 579, 265–269 (2020).
9. R. Lu et al., Lancet 395, 565–574 (2020).
10. J. Ma, “Coronavirus: China’s first confirmed Covid-19 case traced back to November 17” South China Morning Post, 13 March 2020; www.scmp.com/news/china/society/article/3074951/coronavirus-chinas-first-confirmed-covid-19-case-traced-back.
11. A. Rambaut, “Phylogeographic Analysis | 176 genomes | 6 Mar 2020” Virolological (2020); https://virolological.org/t/phylogeographic-analysis-176-genomes-6-mar-2020/356.
12. S. Dushene et al., Virus Evol. 6, ves061 (2020).
13. K. G. Andersen, A. Rambaut, W. I. Lipkin, E. C. Holmes, R. F. Garry, Nat. Med. 26, 450–452 (2020).
14. L. du Plessis, D. Pybus, “Further musings on the tMRCA,” Virolological (2020); https://virolological.org/t/further-musings-on-the-tmrca/340.
15. N. R. Faria et al., Science 346, 56–61 (2014).
16. M. Worobey et al., Nature 455, 661–664 (2008).
17. B. F. Keel et al., Science 333, 523–526 (2006).
18. T. Bedford et al., Science 370, 571–575 (2020).
19. Q. Bi et al., Lancet Infect. Dis. 20, 911–919 (2020).
20. M. A. Suzuki et al., Virus Evol. 4, vey016 (2018).
21. L. Pips, H. Wang, J. P. Huelsenbeck, R. Nielsen, Mol. Biol. Evol. 10.1093/molbev/msaa336 (2020).
22. X. Hao et al., Nature 584, 420–424 (2020).
23. N. Moshiri, M. Raggonet-Cronin, J. D. Werthem, S. Mirarab, Bioinformatics 35, 1852–1861 (2019).
24. R. Laanmäe et al., Science 370, 691–697 (2020).
25. A. Eno, S. Abbott, A. J. Kucharski, S. Funk, Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group, Welcome Open Res. 5, 67 (2020).
26. X.-K. Xu et al., Clin. Infect. Dis. 71, 3163–3167 (2020).
27. D. C. Adam et al., Nat. Med. 26, 1714–1719 (2020).
28. H. Li et al., Biosaf. Health 1, 84–90 (2019).
29. M. Worobey et al., Science 370, 564–570 (2020).
30. L. Du Plessis et al., Science 371, 708–712 (2021).
31. A. Deslandes et al., Int J Antimicrob. Agents 55, 106006 (2020).
32. X. Deng et al., Science 369, 582–587 (2020).
33. M. A. Jorden et al., Med. Mortal. Wiki. Rep. 69, 680–684 (2020).
34. G. Chavarría-Miró et al., medRxiv 2020.06.13.20129627 [Preprint]. 13 June 2020. https://doi.org/10.1101/2020.06.13.20129627.
35. G. Gongoro et al., Sci. Total Environ. 778, 146108 (2021).
36. G. A. Rosa et al., Sci. Total Environ. 750, 141711 (2021).
37. A. Amendola et al., Emerg. Infect. Dis. 27, 648–650 (2021).
38. E. G. Norgan, B. Rader, L. Banno, L. Goodwin, J. Biotechnol. 182, 523–531 (2019); Virological 35, 1852–1861 (2019).
39. J. Peccia et al., Nat. Biotechnol. 38, 1164–1167 (2020).
40. E. Volz et al., Nature 10.1038/s41586-021-03470-x (2021).
41. B. Korber et al., Cell 182, 812–827.e19 (2020).
42. S. Lytras, J. Hughes, W. Xia, X. Jiang, D. L. Robertson, bioRxiv 2021.02.22.427830 [Preprint]. 30 January 2021. https://doi.org/10.1101/2021.02.22.427830.
43. M. F. Boris et al., Nat. Microbiol. 5, 1408–1417 (2020).
44. J. Pekar, J. Werthem, Data for “Timing the SARS-CoV-2 Index Case in Hubei Province,” Dryad (2021); https://doi.org/10.5061/dryad.44rf8jm.

ACKNOWLEDGMENTS
We gratefully acknowledge the authors from the originating laboratories and the submitting laboratories, who generated and shared via GISAID the viral genomic sequence data on which this research is based. A complete list acknowledging the authors who submitted the data analyzed in this study can be found in data S1. We thank J. Havens, M. Sanderson, and B. Werthem for fruitful conversations and insight. Funding: J.O.W. acknowledges funding from the National Institutes of Health (AI135992 and AI136056). J.P. acknowledges funding from the National Institutes of Health (TSLMO21271) and the Google Cloud COVID-19 Research Credits Program. M.W. was supported by the David and Lucile Packard Foundation as well as the University of Arizona College of Science. N.M. acknowledges funding from the National Science Foundation (2028040) and the Google Cloud COVID-19 Research Credits Program. Author contributions: Conceptualization: J.O.W.; Methodology: J.P., N.M., M.W., K.S., and J.O.W.; Software: J.P., N.M., and J.O.W.; Validation: J.P. and J.O.W.; Formal analysis: J.P. and J.O.W.; Investigation: J.P. and J.O.W.; Resources: J.O.W.; Data curation: J.O.W.; Writing – original draft: J.P. and J.O.W.; Writing – review & editing: J.P., M.W., K.S., J.O.W., and N.M.; Visualization: J.P. and J.O.W.; Supervision: J.O.W.; Project administration: J.O.W.; and Funding acquisition: J.O.W. and M.W. Competing interests: J.O.W. has received funding from Gilead Sciences, LLC (completed), and the CDC (ongoing) via grants and contracts to his institution unrelated to this research. Data and materials availability: All data used in this analysis are free to access via GISAID. BEAST XML input, FAVITES JSON, and results files are available in Dryad (44). This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.

SUPPLEMENTARY MATERIALS
science.sciencemag.org/content/372/6540/412/suppl/DC1
Materials and Methods Supplementary Text Figs. S1 to S18 Tables S1 to S5 References (42–54) MDAR Reproducibility Checklist Data S1 20 November 2020; accepted 15 March 2021 Published online 18 March 2021 10.1126/science.abl8003